{"DataElement":{"publicId":"6036512","version":"1","preferredName":"Prostate Cancer Ancillary Test Performed Type","preferredDefinition":"Text term that represents the kind of ancillary testing performed for prostate cancer.","longName":"ANCL_TST_PRF_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6036381","version":"1","preferredName":"Prostate Carcinoma Ancillary Study Testing Performed","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_A study that is secondary to another study._A procedure for critical evaluation._Executed and carried through to completion.","longName":"2744055v1.0:6036379v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6036379","version":"1","preferredName":"Ancillary Study Testing Performed","preferredDefinition":"A study that is secondary to another study.:A procedure for critical evaluation.:Executed and carried through to completion.","longName":"C16041:C15336:C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ancillary Study","conceptCode":"C16041","definition":"A study that is secondary to another study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Testing","conceptCode":"C15336","definition":"A procedure for critical evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F89E81C-E9CB-1F20-E053-F662850A1F8A","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F89E81C-E9DC-1F20-E053-F662850A1F8A","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"COOPERM","dateModified":"2017-12-06","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6035459","version":"1","preferredName":"Prostate Testing Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"PROST_TEST_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"DeCipher","valueDescription":"Decipher Prostate Cancer Test","ValueMeaning":{"publicId":"6035475","version":"1","preferredName":"Decipher Prostate Cancer Test","longName":"6035475","preferredDefinition":"A proprietary genetic test that evaluates a prostate cancer tumor for its potential for metastasis. Decipher measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways that are associated with metastasis and aggressive prostate cancer to classify tumors as high, average, or low risk of metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decipher Prostate Cancer Test","conceptCode":"C128181","definition":"A proprietary genetic test that evaluates a prostate cancer tumor for its potential for metastasis. Decipher measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways that are associated with metastasis and aggressive prostate cancer to classify tumors as high, average, or low risk of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F844ABC-A62D-63EB-E053-F662850AF0A4","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F844ABC-A646-63EB-E053-F662850AF0A4","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","deletedIndicator":"No"},{"value":"Oncotype Dx","valueDescription":"Oncotype DX Genomic Prostate Score","ValueMeaning":{"publicId":"6035476","version":"1","preferredName":"Oncotype DX Genomic Prostate Score","longName":"6035476","preferredDefinition":"A proprietary multi-gene assay that analyzes expression of 17 genes across four genetic pathways to predict prostate cancer aggressiveness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Genomic Prostate Score","conceptCode":"C142186","definition":"A proprietary multi-gene assay that analyzes expression of 17 genes across four genetic pathways to predict prostate cancer aggressiveness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F844ABC-A652-63EB-E053-F662850AF0A4","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F844ABC-A66B-63EB-E053-F662850AF0A4","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","deletedIndicator":"No"},{"value":"PCA3","valueDescription":"Prostate Cancer Antigen 3 mRNA Measurement","ValueMeaning":{"publicId":"6035478","version":"1","preferredName":"Prostate Cancer Antigen 3 mRNA Measurement","longName":"6035478","preferredDefinition":"The determination of the amount of prostate cancer antigen 3 mRNA in a biological sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer Antigen 3 mRNA Measurement","conceptCode":"C132379","definition":"The determination of the amount of prostate cancer antigen 3 mRNA in a biological sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F844ABC-A678-63EB-E053-F662850AF0A4","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F844ABC-A691-63EB-E053-F662850AF0A4","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","deletedIndicator":"No"},{"value":"4K","valueDescription":"4Kscore","ValueMeaning":{"publicId":"6035479","version":"1","preferredName":"4Kscore","longName":"6035479","preferredDefinition":"A proprietary blood test for prostate cancer screening that measures four kallikrein markers (total, free, and intact prostate-specific antigen, and human kallikrein-related peptidase 2 [hK2]).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"4Kscore","conceptCode":"C142184","definition":"A proprietary blood test for prostate cancer screening that measures four kallikrein markers (total, free, and intact prostate-specific antigen, and human kallikrein-related peptidase 2 [hK2]).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F844ABC-A69D-63EB-E053-F662850AF0A4","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F844ABC-A6B6-63EB-E053-F662850AF0A4","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","deletedIndicator":"No"},{"value":"PHI","valueDescription":"Prostate Health Index","ValueMeaning":{"publicId":"5034410","version":"1","preferredName":"Prostate Health Index","longName":"5034410","preferredDefinition":"An assay system that indirectly measures the amount of three forms of prostate-specific antigen (PSA) in a patient serum sample and then uses those values to calculate a score that estimates the patient's probability of having prostate cancer. The PSA forms that are examined are total PSA, free PSA and an isoform of PSA that has a propeptide comprised of two amino acid residues ([-2]proPSA).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Health Index","conceptCode":"C123798","definition":"An assay system that indirectly measures the amount of three forms of prostate-specific antigen (PSA) in a patient serum sample and then uses those values to calculate a score that estimates the patient's probability of having prostate cancer. The PSA forms that are examined are total PSA, free PSA, and an isoform of PSA that has a propeptide comprised of two amino acid residues ([-2]proPSA).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"22162462-DDC6-CDF4-E050-BB89AD4310DB","latestVersionIndicator":"Yes","beginDate":"2015-10-14","endDate":null,"createdBy":"COLBERTM","dateCreated":"2015-10-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F844ABC-A6C0-63EB-E053-F662850AF0A4","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","deletedIndicator":"No"},{"value":"NA","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5035616","version":"1","preferredName":"Not Applicable","longName":"5035616","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"223B305D-E0E3-6C83-E050-BB89AD433DFD","latestVersionIndicator":"Yes","beginDate":"2015-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F53DD3E-D472-67F3-E053-F662850AAB6B","beginDate":"2017-12-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F53DD3E-D47C-67F3-E053-F662850AAB6B","beginDate":"2017-12-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","deletedIndicator":"No"},{"value":"Path. Opinion","valueDescription":"Pathology Review","ValueMeaning":{"publicId":"2570563","version":"1","preferredName":"Pathology Review","longName":"2570563","preferredDefinition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.: The act of appraisal, evaluation, or analysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathology","conceptCode":"C18189","definition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Review","conceptCode":"C42729","definition":"The act of appraisal, evaluation, or analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E0B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"COOPERM","dateModified":"2017-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F53DD3E-D490-67F3-E053-F662850AAB6B","beginDate":"2017-12-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","deletedIndicator":"No"},{"value":"Bx","valueDescription":"Biopsy","ValueMeaning":{"publicId":"5043459","version":"1","preferredName":"Biopsy","longName":"5043459","preferredDefinition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biopsy","conceptCode":"C15189","definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24217E2F-17D1-718B-E050-BB89AD4318A8","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"LISU","dateModified":"2023-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F53DD3E-D4A5-67F3-E053-F662850AAB6B","beginDate":"2017-12-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","deletedIndicator":"No"},{"value":"Rad","valueDescription":"Radiology","ValueMeaning":{"publicId":"6035460","version":"1","preferredName":"Radiology","longName":"6035460","preferredDefinition":"The branch of medical science dealing with the medical use of X-rays or other penetrating radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiology","conceptCode":"C17059","definition":"The branch of medical science dealing with the medical use of X-rays or other penetrating radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F53DD3E-D4B0-67F3-E053-F662850AAB6B","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-01","modifiedBy":"COOPERM","dateModified":"2018-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F53DD3E-D4C9-67F3-E053-F662850AAB6B","beginDate":"2017-12-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F53DD3E-D45C-67F3-E053-F662850AAB6B","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-01","modifiedBy":"COOPERM","dateModified":"2017-12-06","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Ancillary tests","type":"Preferred Question Text","description":"Ancillary tests","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F90CE7D-F3C6-23C5-E053-F662850A7010","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"COOPERM","dateModified":"2017-12-06","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}